drugset / Trial / NCT02287584

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

NCT02287584

Phase 3 Completed 580 enrolled Sumitomo Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.

Timeline

Start
2014-12
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Blonanserin Small molecule 20 mg Other
Subject Blonanserin Small molecule 40 mg Other
Subject Blonanserin Small molecule 60 mg Other
Subject Blonanserin Small molecule 80 mg Other

Indications